Artificial Intelligence (AI) is rapidly transforming the healthcare industry, and Brainomix, a leading medtech company specializing in AI-powered imaging solutions, has just secured €16.7 million in funding to further develop its cutting-edge AI imaging technology. The investment will accelerate the adoption of AI-driven diagnostics and treatment solutions in stroke care, lung diseases, and precision medicine.
What is Brainomix?
Brainomix is a UK-based AI healthcare startup focused on developing automated imaging solutions that assist doctors in making faster and more accurate diagnoses. Its AI platform is designed to:
🧠 Enhance stroke diagnosis and treatment with real-time brain imaging analysis.
🫁 Improve lung disease detection, including AI-powered imaging for COVID-19 and other respiratory conditions.
🧬 Support precision medicine by personalizing treatment decisions based on AI-driven imaging insights.
The company’s flagship product, e-Stroke, is already being used in hospitals worldwide to speed up stroke diagnosis and improve patient outcomes.
How Will Brainomix Use the €16.7 Million Funding?
The newly secured €16.7 million investment will be used to:
✅ Enhance AI imaging technology to improve accuracy and expand its applications.
✅ Accelerate international expansion, bringing Brainomix solutions to more hospitals and healthcare systems.
✅ Strengthen research and development in AI-powered diagnostics and treatment strategies.
✅ Expand partnerships with pharmaceutical companies and healthcare providers to drive adoption of AI in medical imaging.
Investors Betting on AI in Healthcare
The funding round was backed by leading venture capital firms and strategic healthcare investors who recognize the potential of AI-driven imaging solutions to transform diagnostics and treatment. With growing demand for faster, more precise medical imaging, Brainomix is positioned to be a key player in the future of AI-powered healthcare.
Why AI Imaging is a Game-Changer for Healthcare
🚀 AI imaging reduces diagnosis time for critical conditions like strokes, where every second counts.
🏥 Automated analysis improves accuracy, minimizing human errors and enhancing treatment outcomes.
📊 AI-driven insights support precision medicine, allowing doctors to tailor treatments for individual patients.
🌍 AI imaging is scalable, making high-quality diagnostics accessible even in regions with limited medical expertise.
What’s Next for Brainomix?
With this fresh funding, Brainomix plans to scale its AI solutions globally and continue innovating in the field of medical imaging. The company’s AI-powered stroke diagnosis tool is already widely used, and further advancements in lung disease and precision medicine applications will help expand its impact on global healthcare.
Final Thoughts
The €16.7 million investment in Brainomix highlights the increasing role of AI in revolutionizing medical imaging. As the demand for faster, more accurate, and scalable diagnostic solutions grows, Brainomix’s AI-driven innovations are set to make a significant impact on patient care and clinical decision-making.
